Epigenetic investigation into circulating microRNA 197-3p in sera from patients affected by malignant pleural mesothelioma and workers ex-exposed to asbestos.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 04 2023
20 04 2023
Historique:
received:
12
01
2023
accepted:
07
04
2023
medline:
24
4
2023
pubmed:
21
4
2023
entrez:
20
04
2023
Statut:
epublish
Résumé
The epigenetic role of microRNAs is established at both physiological and pathological levels. Dysregulated miRNAs and their targets appear to be a promising approach for innovative anticancer therapies. In our previous study, circulating miR-197-3p tested dysregulated in workers ex-exposed to asbestos (WEA). Herein, an epigenetic investigation on this circulating miRNA was carried out in sera from malignant pleural mesothelioma (MPM) patients. MiR-197-3p was quantified in MPM (n = 75) sera and comparatively analyzed to WEA (n = 75) and healthy subject (n = 75) sera, using ddPCR and RT-qPCR techniques. Clinicopathological characteristics, occupational, non-occupational information and overall survival (OS) were evaluated in correlation studies. MiR-197-3p levels, analyzed by ddPCR, were significantly higher in MPM than in WEA cohort, with a mean copies/µl of 981.7 and 525.01, respectively. Consistently, RT-qPCR showed higher miR-197-3p levels in sera from MPM with a mean copies/µl of 603.7, compared to WEA with 336.1 copies/µl. OS data were significantly associated with histologic subtype and pleurectomy. Circulating miR-197-3p is proposed as a new potential biomarker for an early diagnosis of the MPM onset. Indeed, miR-197-3p epigenetic investigations along with chest X-ray, computed tomography scan and spirometry could provide relevant information useful to reach an early and effective diagnosis for MPM.
Identifiants
pubmed: 37081052
doi: 10.1038/s41598-023-33116-z
pii: 10.1038/s41598-023-33116-z
pmc: PMC10119131
doi:
Substances chimiques
Circulating MicroRNA
0
Asbestos
1332-21-4
MicroRNAs
0
MIRN197 microRNA, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6501Informations de copyright
© 2023. The Author(s).
Références
Sci Rep. 2021 Dec 14;11(1):23955
pubmed: 34907223
Oncotarget. 2017 May 17;8(32):53751-53762
pubmed: 28881848
Expert Rev Mol Diagn. 2018 Jan;18(1):7-17
pubmed: 29115895
Mol Med Rep. 2018 Mar;17(3):3921-3927
pubmed: 29286108
Nat Methods. 2013 Oct;10(10):1003-5
pubmed: 23995387
Cell Physiol Biochem. 2018;51(1):470-486
pubmed: 30453289
Gene. 2016 Oct 15;591(2):313-9
pubmed: 27320730
Ther Adv Med Oncol. 2021 Dec 10;13:17588359211061956
pubmed: 34917175
Mol Cancer Res. 2009 Aug;7(8):1234-43
pubmed: 19671678
Front Oncol. 2018 Apr 03;8:91
pubmed: 29666782
Lung Cancer (Auckl). 2020 Jan 08;11:1-11
pubmed: 32021524
Bioengineered. 2021 Dec;12(1):927-936
pubmed: 33734009
World J Surg Oncol. 2021 Feb 3;19(1):39
pubmed: 33536026
Cancer Manag Res. 2019 May 30;11:4997-5012
pubmed: 31239765
Gene. 2015 Apr 10;560(1):77-82
pubmed: 25644077
Cell Death Differ. 2014 May;21(5):774-82
pubmed: 24488097
Front Oncol. 2021 Oct 01;11:679285
pubmed: 34660262
Front Genet. 2014 Jan 30;5:8
pubmed: 24523727
Thorac Surg Clin. 2020 Nov;30(4):395-423
pubmed: 33012429
Lung Cancer. 2015 Jun;88(3):344-8
pubmed: 25863904
Front Oncol. 2017 Nov 29;7:294
pubmed: 29238698
Sci Rep. 2022 Feb 23;12(1):3069
pubmed: 35197510
J Thorac Dis. 2018 Apr;10(Suppl 9):S1003-S1007
pubmed: 29850181
J Cell Biochem. 2019 Mar;120(3):3203-3211
pubmed: 30362153
Oncol Res. 2018 Apr 10;26(3):473-481
pubmed: 29137688
Cancer Cytopathol. 2016 Jan;124(1):28-37
pubmed: 26765063
Bioengineered. 2022 Mar;13(3):4757-4772
pubmed: 35174774
Oncoimmunology. 2015 Jun 4;4(10):e1031440
pubmed: 26451302
Front Cell Dev Biol. 2021 Jan 18;8:534499
pubmed: 33537296
Int J Mol Med. 2020 Oct;46(4):1311-1320
pubmed: 32945345
Mol Oncol. 2020 Oct;14(10):2589-2608
pubmed: 32679610
Mol Cells. 2019 Mar 31;42(3):270-283
pubmed: 30841025
Front Oncol. 2019 Dec 06;9:1366
pubmed: 31867277
Balkan Med J. 2022 Jun 13;39(4):246-254
pubmed: 35695486
BMC Biotechnol. 2016 Aug 18;16(1):60
pubmed: 27538962
Tumour Biol. 2015 Sep;36(9):6725-32
pubmed: 25833695
J Asthma Allergy. 2021 Oct 30;14:1307-1321
pubmed: 34744440
Oncol Lett. 2019 Feb;17(2):2317-2327
pubmed: 30675297
J Oncol. 2022 Jan 11;2022:4889807
pubmed: 35087589
IUBMB Life. 2020 May;72(5):1034-1044
pubmed: 32027089
BMC Res Notes. 2019 Feb 11;12(1):77
pubmed: 30744695
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
Transl Cancer Res. 2021 Apr;10(4):1856-1862
pubmed: 35116507
J Clin Endocrinol Metab. 2006 Sep;91(9):3584-91
pubmed: 16822819
Tumour Biol. 2016 Nov;37(11):14553-14563
pubmed: 27631965
Clin Transl Oncol. 2016 Feb;18(2):153-9
pubmed: 26199015
Oncotarget. 2016 Dec 13;7(50):82700-82711
pubmed: 27716620
Respir Med. 2018 Jan;134:31-41
pubmed: 29413505
Oncol Lett. 2019 Mar;17(3):3607-3614
pubmed: 30867804
J Thorac Dis. 2018 Jan;10(Suppl 2):S311-S321
pubmed: 29507801
Arch Pathol Lab Med. 2018 Jun;142(6):753-760
pubmed: 29480760
Front Cell Dev Biol. 2021 Jun 07;9:619842
pubmed: 34164391
PLoS One. 2017 May 4;12(5):e0176680
pubmed: 28472171
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1825-1829
pubmed: 30060954
Mol Cancer. 2016 Jun 24;15(1):48
pubmed: 27343009
Dis Markers. 2017;2017:9645940
pubmed: 28757678
Front Oncol. 2020 Apr 03;10:445
pubmed: 32318342
J Cancer. 2019 Aug 7;10(19):4603-4613
pubmed: 31528224
PLoS One. 2022 Oct 14;17(10):e0275936
pubmed: 36240245
Thorax. 2021 Nov;76(11):1154-1162
pubmed: 33692175
CA Cancer J Clin. 2019 Sep;69(5):402-429
pubmed: 31283845
J Cell Physiol. 2019 Jul;234(7):9895-9905
pubmed: 30740692
Part Fibre Toxicol. 2010 Mar 22;7:5
pubmed: 20307263
Front Oncol. 2019 Jul 25;9:670
pubmed: 31403031
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2524-2540
pubmed: 32699075
Int J Biol Sci. 2020 Feb 21;16(8):1417-1426
pubmed: 32210729
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Int J Mol Sci. 2018 May 30;19(6):
pubmed: 29848954
Ann Clin Biochem. 2018 Jan;55(1):49-58
pubmed: 29058958
Methods Mol Biol. 2018;1768:445-457
pubmed: 29717458
Thorac Cancer. 2021 Jan;12(1):8-12
pubmed: 33225621
Cancer Manag Res. 2020 Sep 18;12:8663-8674
pubmed: 32982457